DiaMedica Therapeutics Inc. (DMAC)
Largest Insider Buys in Sector
DMAC Stock Price History Chart
DMAC Stock Performance
About DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX trial for the treatment of patients with moderate or severe chronic kidney disease caused by Type I or Type II diabetes; and Phase 2/3 REMEDY2 trials for the treatment of patients with acute ischemic stroke. It is also developing DM300 that is in pre-clinical stage for the treatment of inflammatory …
Insider Activity of DiaMedica Therapeutics Inc.
Over the last 12 months, insiders at DiaMedica Therapeutics Inc. have bought $6.05M and sold $0 worth of DiaMedica Therapeutics Inc. stock.
On average, over the past 5 years, insiders at DiaMedica Therapeutics Inc. have bought $4.26M and sold $3.53M worth of stock each year.
Highest buying activity among insiders over the last 12 months: STAHLBERG JAN (10 percent owner) — $3M. Von Koch Thomas (10 percent owner) — $3M. Wambeke David J. (Chief Business Officer) — $49,200.
The last purchase of 1,200,000 shares for transaction amount of $3M was made by Von Koch Thomas (10 percent owner) on 2024‑06‑28.
List of Insider Buy and Sell Transactions, DiaMedica Therapeutics Inc.
| 2024-06-28 | 10 percent owner | 1.2M 2.6697% | $2.50 | $3M | 0.00% | |||
| 2024-06-28 | 10 percent owner | 1.2M 2.6697% | $2.50 | $3M | 0.00% | |||
| 2023-11-16 | Chief Business Officer | 20,000 0.0542% | $2.46 | $49,200 | +22.59% | |||
| 2023-06-23 | 10 percent owner | 1.47M 4.4481% | $3.40 | $5M | -33.18% | |||
| 2023-06-23 | Chief Business Officer | 38,364 0.1334% | $3.91 | $150,003 | -33.18% | |||
| 2023-06-23 | director | 65,000 0.2261% | $3.91 | $254,150 | -33.18% | |||
| 2023-06-23 | director | 38,363 0.1334% | $3.91 | $149,999 | -33.18% | |||
| 2023-06-23 | President and CEO | 12,787 0.0445% | $3.91 | $49,997 | -33.18% | |||
| 2023-06-23 | CFO and Secretary | 10,000 0.0348% | $3.91 | $39,100 | -33.18% | |||
| 2023-06-23 | director | 12,787 0.0445% | $3.91 | $49,997 | -33.18% | |||
| 2023-04-10 | Chief Business Officer | 468,750 1.8065% | $1.60 | $750,000 | +79.62% | |||
| 2022-12-09 | director | 37,079 0.1402% | $1.43 | $53,023 | +57.34% | |||
| 2022-12-08 | director | 20,000 0.0735% | $1.40 | $28,000 | +55.90% | |||
| 2022-12-07 | director | 22,574 0.086% | $1.40 | $31,604 | +61.15% | |||
| 2022-12-06 | director | 2,300 0.0083% | $1.35 | $3,105 | +57.39% | |||
| 2022-12-05 | director | 35,000 0.14% | $1.39 | $48,493 | +69.08% | |||
| 2022-12-02 | Sale | director | 2.86M 9.0121% | $1.24 | $3.53M | +47.97% | ||
| 2022-12-02 | director | 2.86M 9.0121% | $1.24 | $3.53M | +47.97% | |||
| 2022-12-01 | director | 46,952 0.1775% | $1.20 | $56,334 | +82.08% | |||
| 2022-11-30 | director | 2,970 0.0112% | $1.19 | $3,534 | +82.77% |
Insider Historical Profitability
| Von Koch Thomas | 10 percent owner | 5526435 12.928% | $4.39 | 3 | 1 | +7.4% |
| STAHLBERG JAN | 10 percent owner | 5221608 12.2149% | $4.39 | 1 | 0 | |
| Wambeke David J. | Chief Business Officer | 527114 1.2331% | $4.39 | 3 | 0 | +23.22% |
| TomEnterprise AB | 2855827 6.6806% | $4.39 | 1 | 0 | +16.67% | |
| Giuffre Randall Michael | director | 360355 0.843% | $4.39 | 10 | 0 | +49.77% |
Institutional Investor Ownership
| The Vanguard Group | $2.81M | 2.67 | 1.01M | +26.35% | +$585,442.28 | <0.0001 | |
| Leon G. Cooperman | $2.45M | 2.33 | 883,623 | 0% | +$0 | 0.1 | |
| First Manhattan Co. | $2.35M | 2.24 | 850,038 | +640.81% | +$2.04M | 0.01 | |
| Paragon Associates Paragon Associates Ii Joint Venture | $1.39M | 1.32 | 500,000 | 0% | +$0 | 2.47 | |
| Geode Capital Management | $662,841.00 | 0.63 | 239,235 | +9.35% | +$56,679.58 | <0.0001 |